TELA Bio Inc.

TELA | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.34

+$0.04 (+3.08%)

Sep 22, 2026, 1:20 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.08%

(1D)

Rating

Updated: Aug 18, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $60.18M

1D Range

1.28 1.36

52W Range

0.50 1.66

Valuation (TTM)

PE -1.71

PB -3.72

EV/EBITDA -2.56

Valuation (NTM)

Forward PE N/A

Forward PEG 0.05

Price Target $8.25

Cash Flow

FCF Yield -53.5%

SBC Adj. FCF Yield -59.0%

SBC Impact -10.1%

Margins

Gross Margin 67.8%

Operating Margin -42.6%

FCF Margin -39.6%

Growth (CAGR)

Revenue 3Y | 5Y 17.6% | 26.8%

Dil EPS 3Y | 5Y 39.5% | 31.1%

FCF 3Y | 5Y 16.9% | 6.2%

Returns

ROA -68.9%

ROE 1248.1%

ROIC -80.9%

Financial Health

Net Debt

$25.66M

Current Ratio 2.99

Interest Coverage -11.89

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoratio...

Sector Healthcare

Industry Medical - Devices

Employees 218

IPO Date Nov 6, 2019

Website www.telabio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+123.88%

Buy (3)

Hold (1)

Sell (0)

Analyst Details ➞